LOS ANGELES, March 12, 2018 /PRNewswire-PRWeb/ -- After a series of successful Cannabis Compliance Summits on the West
Insights into Endo-Cannabinoid biology are driving a therapeutic revolution and world class research are opening the gates to a new era of medicine and wellness. The Symposium will provide the opportunity to hear cutting-edge cannabinoid therapeutics and research into the human Endo-Cannabinoid System.
Critical topics discussed will revolve around how the medical system of the future will integrate cannabinoid therapeutics into clinical practices, institutional reports and funding discussions. Stakeholders in cannabis and cannabinoid-based medicine will gain insights from the leaders on the front-line.
Featured Keynote speakers include:
Roger G. Pertwee, MA, DPhil, DSc, HonFBPhS, Emeritus Professor, School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen; Director of Pharmacology, GW Pharmaceuticals.
Daniele Piomelli, PhD, MD (h.c.), Director, UCI Institute for the Study of Cannabis; Louise Turner Arnold Chair in the Neurosceinces, Professor of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, UC Irvine.
Participating organizations and institutions in attendance include: GW Pharmaceuticals, Columbia Univercity, UCLA, UC Irvine, University of South Carolina, West Los Angeles VA Medical Center and many more.
To register or learn more information regarding the agenda, speakers, and sessions: visit http://infocastinc.com/event/cannabinoid-therapeutics or contact Infocast at 818-888-4444.
About Infocast: For over 30 years, Infocast has produced the highest quality events, tailored to the needs of the industries we serve. We intensively research the marketplace, pulling from an extensive network of experts to give you the information and connections to succeed.
SOURCE Cannabinoid Therapeutics Symposium
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All